View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 4, 2019

Cheplapharm to buy US and Canada rights to Seroquel

German pharmaceutical firm Cheplapharm Arzneimittel has signed an agreement to acquire commercial rights for Seroquel and Seroquel XR in the US and Canada from AstraZeneca.

German pharmaceutical firm Cheplapharm Arzneimittel has signed an agreement to acquire commercial rights for Seroquel and Seroquel XR in the US and Canada from AstraZeneca.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Seroquel is an immediate-release formulation of quetiapine fumarate for the treatment of schizophrenia and bipolar disorder.

Meanwhile, Seroquel XR is an extended-release formulation for major depressive disorder and generalised anxiety disorder.

The drugs have lost their patent protection in multiple markets, including the US and Canada. Last year, Seroquel and Seroquel XR recorded $36m and $79m in sales, respectively, in these countries.

AstraZeneca will receive $35m in upfront payment from Cheplapharm and is also eligible for up to $6m in future sales-contingent payments.

The divestiture is part of AstraZeneca’s strategy to reinvest in core therapy areas. The deal is not associated with any closing conditions and became effective upon signing, said the company.

AstraZeneca agreed to produce and supply the drugs to Cheplapharm during a transition period.

In October the company agreed to sell the commercial rights for the drugs in Europe and Russia to Cheplapharm. The transaction is subject to customary closing conditions and regulatory clearances and is expected to close over the coming months.

AstraZeneca BioPharmaceuticals business unit executive vice-president Ruud Dobber said: “This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas.

“Cheplapharm recently agreed to acquire the commercial rights to Seroquel and Seroquel XR in most European markets and Russia from AstraZeneca and this new agreement will help ensure continued patient access to this important established medicine in North America as well.”

AstraZeneca agreed in May last year to sell rights to Seroquel and Seroquel XR in the UK, Japan, China and other international markets to Luye Pharma.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology